Profiel
John Fry worked at Alios BioPharma, Inc. from 2011 to 2018, where he held the position of VP-Head-Early Development & Infectious Diseases from 2014 to 2018.
He then joined Aligos Therapeutics, Inc. in 2018 and worked there until 2023 as the Executive Vice President-Clinical Development.
Prior to his professional career, Mr. Fry completed his undergraduate degree at the University of Sussex.
Eerdere bekende functies van John Fry
| Bedrijven | Functie | Einde |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2023 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | 01-11-2014 |
Opleiding van John Fry
| University of Sussex | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |